• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

IFNL3 Gene Record

  • Summary
  • Interactions
  • Claims
  • IFNL3 282617 Druggable Genome

    Alternate Names:

    282617
    INTERFERON LAMBDA 3
    IFNL3
    IFN-lambda-3
    IFN-lambda-4
    IL-28B
    IL-28C
    IL28B
    IL28C
    607402
    18365
    ENSG00000197110
    OTTHUMG00000182805
    PA134952671

    Gene Info:

    Gene Biotype PROTEIN_CODING
    (1 More Sources)

    Gene Categories: Category Details

    DRUGGABLE GENOME

    Publications:

    Cusato J et al., 2015, Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics., Int J Antimicrob Agents
    Muir AJ et al., 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens., Clin Pharmacol Ther
    Poordad F et al., 2012, Factors that predict response of patients with hepatitis C virus infection to boceprevir., Gastroenterology
    O'Brien TR et al., 2017, IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir., Gastroenterology
    Zeuzem S et al., 2013, Faldaprevir and deleobuvir for HCV genotype 1 infection., N Engl J Med
    D'Offizi G et al., 2017, Clinical and virological predictors of sustained response with an interferon-based simeprevir regimen for patients with chronic genotype 1 hepatitis C virus infection., New Microbiol
    Manns M et al., 2014, Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial., Lancet
    Forns X et al., 2014, Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial., Gastroenterology
    Khan AJ et al., 2019, Polymorphism in interferon λ3/interleukin-28B gene and risk to noncirrhotic chronic hepatitis C genotype 3 virus infection and its effect on the response to combined daclatasvir and sofosbuvir therapy., J Med Virol
    Ramamurthy N et al., 2018, Impact of Interferon Lambda 4 Genotype on Interferon-Stimulated Gene Expression During Direct-Acting Antiviral Therapy for Hepatitis C., Hepatology
    O'Brien TR et al., 2017, Race or genetic makeup for hepatitis C virus treatment decisions?, Hepatology
    Akuta N et al., 2017, Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan., J Med Virol
    O'Brien TR et al., 2014, Subgroup differences in response to 8 weeks of ledipasvir/sofosbuvir for chronic hepatitis C., Open Forum Infect Dis
    El-Khazragy N et al., 2018, IL-28β gene polymorphism determines virological response to PEGylated interferon therapy in hepatitis C virus genotype 4 Egyptian patients., J Cell Biochem
    Sakhaee F et al., 2017, The impact of genetic variation in IL28B, IFNL4 and HLA genes on treatment responses against chronic hepatitis C virus infection., Infect Genet Evol
    Asnavandi M et al., 2017, EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C., Genes Immun
    Gauthiez E et al., 2017, A systematic review and meta-analysis of HCV clearance., Liver Int
    Kamal AM et al., 2016, Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection., Rom J Morphol Embryol
    Sedighimehr P et al., 2017, IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C., Arch Virol
    Ranjan P et al., 2016, Association of interleukin-28B rs12979860 and rs8099917 polymorphisms with sustained viral response in hepatitis C virus genotype 1 and 3 infected patients from the Indian subcontinent., Indian J Med Microbiol
    Mansoor S et al., 2016, Can IFNL3 polymorphisms predict response to interferon/ribavirin treatment in hepatitis C patients with genotype 3?, J Gen Virol
    El-Bendary M et al., 2015, Interleukin 28B Polymorphism Predicts Treatment Outcome Among Egyptian Patients Infected With HCV Genotype 4., Hepatogastroenterology
    Suzuki M et al., 2016, Peginterferon Therapy in Children With Chronic Hepatitis C: A Nationwide, Multicenter Study in Japan, 2004-2013., J Pediatr Gastroenterol Nutr
    Schwarz KB et al., 2016, Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C., J Pediatr Gastroenterol Nutr
    O'Brien TR et al., 2015, Comparison of functional variants in IFNL4 and IFNL3 for association with HCV clearance., J Hepatol
    Holmes JA et al., 2015, The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3., Aliment Pharmacol Ther
    Fathy MM et al., 2015, Assessment of interleukin 28B genotype as a predictor of response to combined therapy with pegylated interferon plus ribavirin in HCV infected Egyptian patients., Cytokine
    Nadia K et al., 2015, The complete title: The effect of interleukin-28B rs12979860 polymorphism on the therapeutic response of Moroccan patients with chronic hepatitis C., Gene
    Cariani E et al., 2016, Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis., Pharmacogenomics J
    Zheng H et al., 2015, IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis., Clin Res Hepatol Gastroenterol
    Terczyńska-Dyla E et al., 2014, Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes., Nat Commun
    Knapp S et al., 2014, Detection of allele specific differences in IFNL3 (IL28B) mRNA expression., BMC Med Genet
    Hézode C et al., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study., Gut
    Umemura T et al., 2014, KIR3DL1-HLA-Bw4 combination and IL28B polymorphism predict response to Peg-IFN and ribavirin with and without telaprevir in chronic hepatitis C., Hum Immunol
    Eslam M et al., 2014, IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection., J Hepatol
    Fujino H et al., 2014, Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C., J Gastroenterol
    Nozawa Y et al., 2014, Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients., Tissue Antigens
    Covolo L et al., 2014, The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection., Aliment Pharmacol Ther
    Tsubota A et al., 2014, Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b., J Gastroenterol Hepatol
    Ragheb MM et al., 2014, Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4., Liver Int
    Franco S et al., 2014, IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients., AIDS
    Seto WK et al., 2013, Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection., J Viral Hepat
    Piluso A et al., 2013, Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study., J Viral Hepat
    Stenkvist J et al., 2013, HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphism., J Viral Hepat
    Pol S et al., 2013, Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure., J Hepatol
    Shimoyama Y et al., 2013, Effects of IL-28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C., Hepatol Res
    Luo Y et al., 2013, Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis., Gene
    Riva E et al., 2012, Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients., J Viral Hepat
    Kobayashi M et al., 2012, Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus., J Gastroenterol
    Antaki N et al., 2012, IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5., Gut
    de Castellarnau M et al., 2012, Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients., PLoS One
    Liu CH et al., 2012, Interleukin 28B genetic polymorphisms and viral factors help identify HCV genotype-1 patients who benefit from 24-week pegylated interferon plus ribavirin therapy., Antivir Ther
    Lopez-Rodriguez R et al., 2011, Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C., Clin Pharmacol Ther
    Venegas M et al., 2011, IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients., World J Gastroenterol
    Asselah T et al., 2012, IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C., J Hepatol
    Ridruejo E et al., 2011, Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin., Ann Hepatol
    Lyoo K et al., 2011, Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin., J Clin Virol
    Hayashi K et al., 2011, Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy., Liver Int
    Toyoda H et al., 2011, Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene., J Med Virol
    Giannini EG et al., 2011, IL28B rs12979860 C/T polymorphism in elderly chronic hepatitis C patients treated with pegylated-interferon and ribavirin., Aliment Pharmacol Ther
    Lindh M et al., 2011, Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus., J Infect Dis
    Pineda JA et al., 2011, Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients., AIDS
    Labarga P et al., 2011, Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse., AIDS
    Hashimoto Y et al., 2011, Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol
    Coto-Llerena M et al., 2011, Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation., Am J Transplant
    Liao XW et al., 2011, Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population., Antivir Ther
    Lagging M et al., 2011, Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms., PLoS One
    Eurich D et al., 2011, Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation., Liver Transpl
    Moghaddam A et al., 2011, IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection., Hepatology
    Sakamoto N et al., 2011, Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b., J Med Virol
    Chen JY et al., 2011, IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection., Genes Immun
    Yu ML et al., 2011, Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients., Hepatology
    Suzuki F et al., 2011, Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir., Hepatology
    Scherzer TM et al., 2011, Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin., J Hepatol
    Kawaoka T et al., 2011, Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b., J Hepatol
    Sarrazin C et al., 2011, Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients., J Hepatol
    Hayes CN et al., 2011, HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut
    Medrano J et al., 2010, Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV., Clin Infect Dis
    Pineda JA et al., 2010, Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus., Clin Infect Dis
    Stättermayer AF et al., 2011, Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C., Clin Gastroenterol Hepatol
    Akuta N et al., 2010, Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin., Hepatology
    Mangia A et al., 2010, An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response., Gastroenterology
    Montes-Cano MA et al., 2010, Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes., Hepatology
    Honda M et al., 2010, Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C., Gastroenterology
    Thompson AJ et al., 2010, Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus., Gastroenterology
    Rauch A et al., 2010, Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study., Gastroenterology
    Suppiah V et al., 2009, IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy., Nat Genet
    Tanaka Y et al., 2009, Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C., Nat Genet
    Ge D et al., 2009, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance., Nature
  • SOFOSBUVIR   IFNL3

    Interaction Score: 14.55

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Ledipasvir,Sofosbuvir
    Combination therapy Sofosbuvir,Velpatasvir
    Combination therapy Sofosbuvir,Velpatasvir,Voxilaprevir

    PMIDs:
    30431653 29534310 29107709 28100007 27357737 25734178


    Sources:
    PharmGKB FDA

  • RIBAVIRIN   IFNL3

    Interaction Score: 9.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30450628 28739427 28703131 28261910 28072888 27833958 27714501 27514956 27498543 26902034 26825765 26284539 26186989 26032235 26003758 25958342 25918016 25769643 25534433 25287681 25080450 24929144 24907224 24768758 24602923 24362944 24355007 24308755 24117654 24102823 24096968 24072198 23730840 23490377 23383658 23321318 23281610 23142377 22863269 22626609 22438096 22345656 22328925 22301466 21993426 21987611 21951981 21911885 21907615 21745312 21739446 21726252 21606533 21572301 21537116 21503910 21466653 21447862 21390311 21384511 21374656 21360545 21346780 21254157 21246582 21145807 21112660 21112657 21068134 20964522 20804372 20728570 20648473 20621700 20578254 20434452 20399780 20060832 19749758 19749757 19684573


    Sources:
    PharmGKB

  • LEDIPASVIR   IFNL3

    Interaction Score: 9.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Ledipasvir,Sofosbuvir

    PMIDs:
    28100007 27357737 25734178


    Sources:
    PharmGKB FDA

  • DACLATASVIR   IFNL3

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30431653 25080450


    Sources:
    PharmGKB FDA

  • DASABUVIR   IFNL3

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • TELAPREVIR   IFNL3

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24362944 24117654 24096968 23321318 21246582 20648473


    Sources:
    PharmGKB FDA

  • VOXILAPREVIR   IFNL3

    Interaction Score: 5.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Sofosbuvir,Velpatasvir,Voxilaprevir

    PMIDs:
    29107709


    Sources:
    PharmGKB FDA

  • VELPATASVIR   IFNL3

    Interaction Score: 5.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Sofosbuvir,Velpatasvir,Voxilaprevir
    Combination therapy Sofosbuvir,Velpatasvir

    PMIDs:
    29107709


    Sources:
    PharmGKB FDA

  • DELEOBUVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23944300


    Sources:
    PharmGKB

  • OMBITASVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir
    Combination therapy Ombitasvir,Paritaprevir,Ritonavir

    PMIDs:
    None found


    Sources:
    FDA

  • ELBASVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Elbasvir,Grazoprevir

    PMIDs:
    None found


    Sources:
    FDA

  • FALDAPREVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23944300


    Sources:
    PharmGKB

  • GRAZOPREVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Elbasvir,Grazoprevir

    PMIDs:
    None found


    Sources:
    FDA

  • PARITAPREVIR   IFNL3

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir
    Combination therapy Ombitasvir,Paritaprevir,Ritonavir

    PMIDs:
    None found


    Sources:
    FDA

  • BOCEPREVIR   IFNL3

    Interaction Score: 2.6

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25836019 24096968 22626609


    Sources:
    PharmGKB FDA

  • SIMEPREVIR   IFNL3

    Interaction Score: 2.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28072888 24907224 24602923


    Sources:
    PharmGKB FDA

  • RITONAVIR   IFNL3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Dasabuvir,Ombitasvir,Paritaprevir,Ritonavir
    Combination therapy Ombitasvir,Paritaprevir,Ritonavir

    PMIDs:
    None found


    Sources:
    FDA

  • Ensembl: ENSG00000197110

    • Version: 101_38

    Alternate Names:
    IFNL3 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • PharmGKB: IFNL3

    • Version: 18-August-2020

    Alternate Names:
    PA134952671 PharmGKB ID

    Gene Info:

    Publications:
    Cusato J et al., 2015, Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics., Int J Antimicrob Agents
    Muir AJ et al., 2014, Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens., Clin Pharmacol Ther
    Poordad F et al., 2012, Factors that predict response of patients with hepatitis C virus infection to boceprevir., Gastroenterology

  • HingoraniCasas: ENSG00000197110

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000197110 Gene Symbol
    IFNL3 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • Tempus: IFNL3

    • Version: 11-November-2018

    Alternate Names:
    IFNL3 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • FDA: IFNL3

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21